BeyondSpring (BYSI) Price to Sales (2020 - 2021)
BeyondSpring's (BYSI) quarterly Price to Sales came in at 521.72 in Q4 2021, down 74.33% year-over-year from 2032.27 in Q4 2020, and down 62.79% quarter-over-quarter from 1402.23 in Q3 2021.
Powered by 
Analysis
BeyondSpring (BYSI) Price to Sales (2020 - 2021) Analysis & Trends
BeyondSpring has disclosed Price to Sales across 2 years of filings, most recently posting 521.72 for Q4 2021.
- In Q4 2021, Price to Sales fell 74.33% year-over-year to 521.72; the TTM figure through Sep 2024 stood at 273.04 (changed N/A YoY), while the FY2022 annual figure was 54.27, down 58.42% from the prior year.
- Price to Sales came in at 521.72 for Q4 2021 at BeyondSpring, down from 1402.23 in the prior quarter.
- In the past five years, Price to Sales ranged from a high of 2032.27 in Q4 2020 to a low of 521.72 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 521.72 |
| Sep 30, 2021 | 1,402.23 |
| Jun 30, 2021 | 926.14 |
| Mar 31, 2021 | 982.03 |
| Dec 31, 2020 | 2,032.27 |